Delic Holdings (CSE: DELC, OTCQB: DELCF) announces the appointment of Zak Garcia as Chief Marketing Officer. Previously the CMO of Bulletproof Inc., Garcia has been an advisor since the company's inception. His leadership experience and marketing expertise are expected to enhance Delic's growth in the psychedelic wellness sector. The Board approved 50,000 incentive stock options at $0.55. Garcia aims to support trauma-affected individuals through therapeutic psychedelics, particularly focusing on veterans with PTSD.
Delic Holdings Inc. (DELIC), a company focused on psychedelic wellness, has acquired the Homestead brand and its intellectual property for $50,000. This acquisition enhances DELIC's offerings, including an expected product launch of a modern mushroom grow kit this March aimed at increasing e-commerce sales. DELIC will also leverage Homestead's heritage and extensive IP to attract consumers on its platform, Reality Sandwich, which recently saw record traffic of over 200,000 unique visitors monthly. CEO Matt Stang highlighted the strategic importance of this acquisition for enhancing shareholder value.
DELIC Holdings Inc. (DELCF) announced the appointment of Kyle Snook to its Board of Advisors, effective March 2, 2021. Snook, previously COO of Actify Neurotherapies, brings extensive experience in mental health treatments, particularly IV Ketamine therapy. He aims to enhance DELIC's capacity to provide innovative therapies for mental health patients, especially those impacted by COVID-19. The Company also granted him 50,000 stock options at an exercise price of $0.58. DELIC focuses on psychedelic wellness, highlighting its commitment to addressing the growing demand for these treatments.
Delic Holdings Inc. (DELC, OTCQB: DELCF) has signed a binding letter agreement to acquire Ketamine Infusion Centers LLC (KIC), which operates clinics in Arizona and California. KIC reported revenues exceeding USD $1.5 million since 2019 and has delivered over 4,000 treatments. The transaction will allow DELIC to diversify its portfolio and establish a presence in the ketamine treatment space. The acquisition is valued at USD $2.25 million and includes performance-based shares, positioning DELIC for future expansion.